Search research articles
Contact Us
Filters
Showing results (841-850 of 856) with videos related to
Page
of 86
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2003
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
C-H Köhne, J Wils, M Lorenz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 18, 2011
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor
Jinsheng Yu, Hrishikesh Deshmukh, Jacqueline E Payton, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 31, 2010
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma
Nadia N Laack, Brian Patrick O'Neill, Karla V Ballman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
T André, D Vernerey, S A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
British Journal of Cancer
|
April 20, 2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy, J-Y Douillard, C Twelves, et al.
Tumori
|
July 25, 1998
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group
J Wils, T Sahmoud, A Sobrero, et al.
Page
of 86
Search research articles
Search
Showing results (841-850 of 856) with videos related to
Sort By:
Page
of 86
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2003
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
C-H Köhne, J Wils, M Lorenz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 18, 2011
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor
Jinsheng Yu, Hrishikesh Deshmukh, Jacqueline E Payton, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 31, 2010
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma
Nadia N Laack, Brian Patrick O'Neill, Karla V Ballman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
T André, D Vernerey, S A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S Stintzing, P Wirapati, H-J Lenz, et al.
British Journal of Cancer
|
April 20, 2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy, J-Y Douillard, C Twelves, et al.
Tumori
|
July 25, 1998
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group
J Wils, T Sahmoud, A Sobrero, et al.
Page
of 86